EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Early and Late Toxicities of Chimeric Antigen Receptor T-Cells

Rebecca Epperly, Victoria M Giordani, Lekha Mikkilineni, Nirali N Shah

Hematology/Oncology Clinics of North America · 2023-12 · 37 (6) · 1169-1188

DOI: 10.1016/j.hoc.2023.05.010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Hematology/Oncology Clinics of North America, 2023-12. Verfasst von Rebecca Epperly und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 1130, Memphis, TN 3…. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 120 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS, National Cancer Institute, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As chimeric antigen receptor (CAR) T-cell therapy is increasingly integrated into clinical practice across a range of malignancies, identifying and treating inflammatory toxicities will be vital to success. Early experiences with CD19-targeted CAR T-cell therapy identified cytokine release syndrome and neurotoxicity as key acute toxicities and led to unified initiatives to mitigate the influence of these complications. In this section, we provide an update on the current state of CAR T-cell-related toxicities, with an emphasis on emerging acute toxicities affecting additional organ systems and considerations for delayed toxicities and late effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansReceptors, Antigen, T-CellImmunotherapy, AdoptiveT-Lymphocytes

Stichwörter der Autor:innen

Bone marrow dysfunctionChimeric antigen receptor T-cellsCytokine release syndromeCytopeniaImmune effector cell-associated neurotoxicity syndromeInfectious complications

Substanzen

Receptors, Chimeric AntigenReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS 1130, Memphis, TN 38105, USA.
  • Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Building 10, Room 1W-3750, 9000 Rockville Pike MSC 1104, Bethesda, MD 20892, USA; Pediatric Hematology/Oncology, Johns H…
  • Blood and Marrow Transplantation & Cellular Therapy, Stanford University, Palo Alto, CA, USA; Stanford School of Medicine, 300 Pasteur Drive, Room H0101, Stanford, CA 94305, USA.
  • Pediatric Oncology Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Building 10, Room 1W-3750, 9000 Rockville Pike MSC 1104, Bethesda, MD 20892, USA. Electronic address: nirali.shah@nih.go…

Förderung

  • Intramural NIH HHS
  • National Cancer Institute
  • National Institutes of Health

Zitieren

APA

Epperly, R., Giordani, V. M., Mikkilineni, L., & Shah, N. N. (2023). Early and Late Toxicities of Chimeric Antigen Receptor T-Cells. Hematology/Oncology Clinics of North America, 37(6), 1169-1188. https://doi.org/10.1016/j.hoc.2023.05.010

Vancouver

Epperly R, Giordani VM, Mikkilineni L, Shah NN. Early and Late Toxicities of Chimeric Antigen Receptor T-Cells. Hematology/Oncology Clinics of North America. 2023;37(6):1169-1188. doi:10.1016/j.hoc.2023.05.010

BibTeX
@article{Epperly2023,
  author = {Epperly, Rebecca and Giordani, Victoria M and Mikkilineni, Lekha and Shah, Nirali N},
  title = {Early and Late Toxicities of Chimeric Antigen Receptor T-Cells},
  journal = {Hematology/Oncology Clinics of North America},
  year = {2023},
  volume = {37},
  number = {6},
  pages = {1169--1188},
  doi = {10.1016/j.hoc.2023.05.010}
}
Kostenlos starten →